Know When It's Time to Adjust Your Patients' CMV Antiviral Treatment

Eurofins Viracor offers the first commercially available genotypic sequencing tests to help healthcare professionals make informed treatment decisions.

Human Cytomegalovirus (CMV) infections are a major cause of morbidity and mortality among immunocompromised patients. When healthcare providers suspect treatment failure due to antiviral resistance, proper patient management requires CMV resistance analysis — laboratory testing should be used for confirmation, as treatment modification based solely on clinical suspicion may result in added toxicity and increased risks for the patient.

Genotypic sequencing to identify CMV resistance offers a fast turnaround time, a broad range of antiviral resistance information, and information concerning new drugs as they become available— all data you need to help determine if it's time to adjust treatment.

At Viracor, our Mutation Surveillance Program uses nucleic acid sequence databases and journal research to verify new genetic polymorphisms. This program aids in rapid identification of new drugs available for use, like maribavir and letermovir, which allows us to update our genotypic resistance sequencing assays to include reporting for the newest drugs available.

Learn how we can help your hospital or lab streamline your CMV sample collection, turnaround time and testing results.

CAP Accredited. CLIA Licensed. NY State Certified.